Clinical trials: Kidney Cancer
Metastatic Renal Cell Carcinoma
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Immune therapies, such as a IL-2, for metastatic renal cell carcinoma (mRCC) are designed to mobilize immune effector cells that recognize and destroy cancer.
- Trial name
- NCT00913913
- Testing
- DC vaccine, Bevacizumab, IL-2
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Clear Cell Renal Cell Carcinoma
Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
- Trial name
- RCCSCAN (NCT03185182)
- Testing
- Ioflupane I123
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Region Skane
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated…
- Trial name
- CheckMate 374 (NCT02596035)
- Testing
- Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Cancer of Kidney, Kidney Cancer
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
- Conditions
- Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney
- Trial name
- NCT00199888
- Testing
- 124-Iodine-cG250 (124I-cG250)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ludwig Institute for Cancer Research
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney…
- Trial name
- NCT00403169
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Carcinoma, Renal Cell
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1).
- Trial name
- NCT00113529
- Testing
- Gefitinib + Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Renal Cancer
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
This study tests a new medication for treatment of kidney cancer, called BEZ235. This medication works by blocking several mechanisms that the cancer needs to grow and survive.
- Trial name
- NCT01453595
- Testing
- BEZ235
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
- Trial name
- NCT03294083
- Testing
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 95 people
- Sponsor
- SillaJen, Inc.
Metastatic Melanoma, Metastatic Kidney Cancer
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Background: Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
- Trial name
- NCT00328861
- Testing
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Kidney Cancer
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Background: Papillary Renal Cell Cancer (RCC) is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which…
- Trial name
- NCT02019693
- Testing
- INC280
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Carcinoma
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is…
- Trial name
- CheckMate-67T (NCT04810078)
- Testing
- Nivolumab and rHuPH20, Nivolumab
- Where
- 89 sites in United States, Argentina and 15 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Renal Malignant Tumor
Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them.
- Trial name
- NCT03821376
- Testing
- Contrast enhanced ultrasound with Lumason
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University